| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/17/2005 | US20050037948 Calcium phosphopeptide complexes |
| 02/17/2005 | US20050037496 Polyampholytes for delivering polyions to a cell |
| 02/17/2005 | US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer |
| 02/17/2005 | US20050037423 radionuclide-coded labels used for mass spectrometric analysis of proteins; Proteomics |
| 02/17/2005 | US20050037401 Photocleavable DNA transfer agent |
| 02/17/2005 | US20050037374 uses nanoparticle-based assemblies, which comprise a nanoparticle, a surrogate marker and detectors; efficient and accurate means for diagnosing a condition, disease, or disorder and for focused treatment regimens; for identifying the presence of a target analyte/biomarker in a sample of bodily fluids |
| 02/17/2005 | US20050037339 Methods of selecting internalizing antibodies |
| 02/17/2005 | US20050037101 Preventative effects of morinda citrifolia on mammary breast cancer |
| 02/17/2005 | US20050037096 Dispersed solid-containing complex carbohydrate |
| 02/17/2005 | US20050037093 Treatment of nail infections with no |
| 02/17/2005 | US20050037091 Composition comprising paracetamol and a bitterness masking component |
| 02/17/2005 | US20050037088 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/17/2005 | US20050037087 Microcapsular composition comprising core, including at least one active ingredient in combination with an oil or mixture of oils, wherein oils alone or in combination with active ingredient have specific gravity higher than that of water; microcapsules can be easily isolated by precipitation |
| 02/17/2005 | US20050037083 Activating a water insoluble drug in aqueous solution; freeze drying; intravenous injection; sonicating evaporation |
| 02/17/2005 | US20050037081 Novel formulation |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037075 Targeted delivery of controlled release polymer systems |
| 02/17/2005 | US20050037074 Treating adrenal dysfunction in a patient by administering a pharmaceutically effective amount of a combined glucocorticoid such as hydrocortisone and a delivery vehicle, wherein delivery vehicle provides for delayed and sustained release of glucorticoid; congenital adrenal hyperplasia |
| 02/17/2005 | US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 02/17/2005 | US20050037068 Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
| 02/17/2005 | US20050037067 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds |
| 02/17/2005 | US20050037062 In combination with another active ingredient capable of potentiating the effects of the azetidine compound in a system comprising a phospholipid, or a combination of Miglyol, capriol and cremophor; for preparing chemically and physically stable pharmaceutical compositions |
| 02/17/2005 | US20050037061 Remedies for mammary cancer |
| 02/17/2005 | US20050037060 topical mixture of minoxidil or salts, solubilizers, solvents and cosolvents, used for the treatment of alopecia |
| 02/17/2005 | US20050037040 cosmetics used for treatment of skin disorders |
| 02/17/2005 | US20050037035 comprising sphingoids used as cosmetic for topical application with animals having fur covered skins for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur; skin disorders |
| 02/17/2005 | US20050037031 applying to the interior of the nasal cavity a cream which physically blocks communication between the smells and the olfactory nerves in the nasal cavity; dietetics |
| 02/17/2005 | US20050037026 such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037001 APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production |
| 02/17/2005 | US20050036995 Immunogens; tumor antigens; kits |
| 02/17/2005 | US20050036984 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof |
| 02/17/2005 | US20050036983 In vivo use of water absorbent polymers |
| 02/17/2005 | US20050036977 Water insoluble substance complexed with ion exchange resin; rapid-disintegrating tablet/film; effervescence |
| 02/17/2005 | US20050036973 Medical polymers and uses thereof |
| 02/17/2005 | US20050036953 Topical compositions of ammonium lactate |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | US20050036948 Radiolabeled annexins |
| 02/17/2005 | DE10333317A1 Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) Formulation for protein drugs without the addition of human serum albumin (HSA) |
| 02/17/2005 | CA2844154A1 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | CA2535235A1 Topical composition comprising terbinafine and hydrocortisone |
| 02/17/2005 | CA2535045A1 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 02/17/2005 | CA2534983A1 Methods and devices for the treatment of intervertebral discs |
| 02/17/2005 | CA2534870A1 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | CA2534708A1 Targeted carrier fusions for delivery of chemotherapeutic agents |
| 02/17/2005 | CA2534687A1 Magnetic nanoparticle compositions, and methods related thereto |
| 02/17/2005 | CA2534484A1 Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2534418A1 Conjugates of hydroxyalkyl starch and g-csf |
| 02/17/2005 | CA2534412A1 Conjugates of a polymer and a protein linked by an oxime linking group |
| 02/17/2005 | CA2534157A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | CA2533182A1 Dry syrup containing loratadine |
| 02/17/2005 | CA2532669A1 Semi-solid systems containing azetidine derivatives |
| 02/17/2005 | CA2532668A1 Emulsifying systems containing azetidine derivatives |
| 02/17/2005 | CA2532566A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | CA2531032A1 Programmed immune responses using a vaccination node |
| 02/17/2005 | CA2530482A1 Self-assembling peptides incorporating modifications and methods of use thereof |
| 02/17/2005 | CA2528273A1 Hydrophilic adhesive compositions for delivery of herbal medicines |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/17/2005 | CA2502148A1 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 02/16/2005 | EP1506786A1 Medicinal compositions containing ghrelin |
| 02/16/2005 | EP1506781A1 Vaginal care composition |
| 02/16/2005 | EP1506221A2 Fap-activated anti-tumor prodrugs |
| 02/16/2005 | EP1506218A2 Reversible modification of membrane interaction |
| 02/16/2005 | EP1506181A1 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| 02/16/2005 | EP1506041A1 Bisphosphonic acids for the treatment and prevention of osteoporosis |
| 02/16/2005 | EP1506019A1 Complexes for the delivery of biologically-active material to cells |
| 02/16/2005 | EP1506018A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 02/16/2005 | EP1506010A2 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/16/2005 | EP1506003A1 Soluble formulations comprising insulin aspart and insulin detemir |
| 02/16/2005 | EP1505995A1 Chewable compositions containing a gel-forming extract of psyllium |
| 02/16/2005 | EP1505987A2 Stable amorphous celecoxib composite and process therefor |
| 02/16/2005 | EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 02/16/2005 | EP1505975A1 Compositions and method for treating infection in cattle and swine |
| 02/16/2005 | EP1505971A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 02/16/2005 | EP1505969A2 Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives |
| 02/16/2005 | EP1505957A1 Matrix type patch containing bronchodilators |
| 02/16/2005 | EP1505956A1 A method to improve surface properties of pharmaceutical tablets |
| 02/16/2005 | EP1505955A1 Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane |
| 02/16/2005 | EP1505941A1 Powder compaction and enrobing |
| 02/16/2005 | EP1505930A2 Drug-delivery endovascular stent and method for treating restenosis |
| 02/16/2005 | EP1399501A4 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug |
| 02/16/2005 | EP1339789B1 Cosmetic, pharmaceutical and dermatological products containing an electrolyte |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1231915B1 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 02/16/2005 | EP1181329B1 Silicone gel containing salicylic acid |
| 02/16/2005 | EP1158014B1 Process for producing biodegradable polyesters |
| 02/16/2005 | EP1140281B1 Thin polymer film drug reservoirs |
| 02/16/2005 | EP1042347A4 Dna pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| 02/16/2005 | EP1021184B1 Use of flunarizine for the topical treatment of ocular hypertension |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582172A Treating canker sores with patches to speed healing and relieve pain |
| 02/16/2005 | CN1582171A Pulmonary administration of chemically modified insulin |
| 02/16/2005 | CN1582170A Parenteral composition of paracetamol |
| 02/16/2005 | CN1582169A Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| 02/16/2005 | CN1582167A Cytokine-inducing material and cytokine-inducing tool |
| 02/16/2005 | CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |